Payment overview · 2025
General Payments
$31,290.93
148 reported records · 26 companies
Healthcare provider profile · identity verified
Sandip Jain, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · GREENVILLE, SC · NPI 1750456869
Verified facts
What the public records show
CMS Open Payments records show Sandip Jain, MD received $31,290.93 in general payments during 2025 across 148 reported records.
Amgen Inc. accounted for 68.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Evrysdi, Gamunex-C, Nuplazid, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuplazid by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Privigen by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Evrysdi as an associated drug or biological on 569 records involving 252 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Evrysdi by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Gamunex-C by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xembify as an associated drug or biological on 5209 records involving 2197 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xembify by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $21,492.02 | 68.7% | 26 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $7,707.43 | 24.6% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $346.81 | 1.1% | 31 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $278.97 | 0.9% | 13 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $195.86 | 0.6% | 12 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $181.85 | 0.6% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $148.96 | 0.5% | 5 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $140.16 | 0.5% | 6 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $88.07 | 0.3% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $83.63 | 0.3% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $65.54 | 0.2% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $61.26 | 0.2% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $60.96 | 0.2% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $53.13 | 0.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $52.36 | 0.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.93 | 0.2% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $49.81 | 0.2% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $43.29 | 0.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $34.44 | 0.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.53 | 0.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.67 | 0.1% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $21.93 | 0.1% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $21.92 | 0.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.40 | 0.1% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $17.73 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.27 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $17,850.00 | 5 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,700.00 | 4 |
| Food and Beverage | $3,098.52 | 127 |
| Travel and Lodging | $2,642.41 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $13,413.08 | 16 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $7,693.19 | 13 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $278.97 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $230.99 | 25 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $212.06 | 22 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $195.86 | 12 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $181.85 | 8 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $140.16 | 6 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $118.35 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $88.07 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $85.46 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $83.63 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $61.26 | 3 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $53.13 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $52.36 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $51.93 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $49.81 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $39.38 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $32.53 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $30.61 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| Evrysdi Normalized: evrysdi |
Drug | Genentech USA, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Evrysdi evrysdi |
2025 | Evrysdi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 83 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Evrysdi open payments reported associated product |
CMS Open Payments — General Payments 569 supporting records · 252 recipient NPIs · example record 1211488410 |
Evrysdi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
83 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Xembify open payments reported associated product |
CMS Open Payments — General Payments 5209 supporting records · 2197 recipient NPIs · example record 1249529389 |
Xembify · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 191 | 53 |
| Pregabalin | Pregabalin | 184 | 38 |
| Gabapentin | Gabapentin | 150 | 40 |
| Primidone | Primidone | 95 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 92 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 17 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 83 | suppressed |
| Clonazepam | Clonazepam | 78 | 15 |
| Levetiracetam | Levetiracetam | 77 | 21 |
| Prednisone | Prednisone | 73 | 18 |
| Baclofen | Baclofen | 72 | 28 |
| Memantine Hcl | Memantine Hcl | 72 | 22 |
| Topiramate | Topiramate | 57 | 19 |
| Tramadol Hcl | Tramadol Hcl | 54 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 49 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 47 | 13 |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Lacosamide | Lacosamide | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 41 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 12 |
| Azathioprine | Azathioprine | 34 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Dalfampridine Er | Dalfampridine | 33 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 33 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 32 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 30 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Zonisamide | Zonisamide | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | 15 |
| Methylprednisolone | Methylprednisolone | 16 | 11 |
| Modafinil | Modafinil | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Kesimpta Pen | Ofatumumab | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Evrysdi | Risdiplam | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Teriflunomide | Teriflunomide | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fingolimod | Fingolimod Hcl | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Xembify | Immune Globulin,gamma(Igg)klhw | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $31,290.93 · 148 records | Amgen Inc. | ACTHAR, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, EPIDIOLEX, Evrysdi, FYCOMPA, Gamunex-C, HYQVIA, Hizentra, INGREZZA, KESIMPTA, Leqembi, NUPLAZID, Ocrevus Zunovo, PONVORY, QULIPTA, Rystiggo, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, ZEPOSIA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Evrysdi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error